GH Research (GHRS) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GH Research (GHRS) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 55.3% versus a gain of 3.0%. Over five years, PAHC leads with a +75.7% price change compared with +20.3% for GHRS. Phibro Animal Health is the larger company by market cap ($1.56 billion vs $1.45 billion), about 1.1 times the size.
Phibro Animal Health pays a dividend yielding 1.25%, while GH Research does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | PAHC |
|---|---|---|
| Share price | $21.11 | $38.30 |
| Market cap | $1.45B | $1.56B |
| 1-day change | +3.23% | +2.41% |
| YTD return | +61.02% | +2.52% |
| 1-year return | +55.28% | +3.04% |
| 5-year return | +20.29% | +75.69% |
| P/E ratio (TTM) | — | 15.76 |
| Forward P/E | — | 9.97 |
| EPS (TTM) | $-0.99 | $2.43 |
| Dividend yield | 0.00% | 1.25% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | — | $1.52B |
| Revenue growth (YoY) | — | +17.12% |
| Net income (latest FY) | — | $99.72M |
| Gross margin | — | 33.76% |
| Operating margin | — | 12.81% |
| Net margin | — | 6.57% |
| 52-week high | $31.44 | $60.08 |
| 52-week low | $12.04 | $28.25 |
| Distance from 52-week high | -32.85% | -36.25% |
| Analyst consensus | none | hold |
| Avg. price target upside | +103.17% | +14.88% |
| Average volume | 294.29K | 236.19K |
| Shares outstanding | 68.64M | 21.11M |
| Employees | 73 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed PAHC by 52.2 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
GHRS vs PAHC FAQ
Which is bigger, GH Research or Phibro Animal Health?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.56B compared with $1.45B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or PAHC?
GHRS returned +55.28% over the past 12 months, compared with +3.04% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, GH Research or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.25%, while GH Research does not currently pay a regular dividend.
Are GH Research and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.